| Filed On | Filing |
|---|---|
| 28 Oct 2026 |
8-K: Results of Operations and Financial Condition
TUDRIQEV first delivered to patients for advanced melanoma on October 6th |
| 16 Sep 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
CERTIFICATE OF AMENDMENT TO THE THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF REPLIMUNE GROUP, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition
TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days |
| 10 Aug 2026 |
8-K: Other Events
Pre-Funded Warrants to Purchase 2,736,340 Shares of Common Stock |
| 07 Aug 2026 |
8-K: Other Events
© 2026 Replimune Group Inc. TUDRIQEV TM (vusolimogene oderparepvec - wtpg ) FDA Accelerated Approval Investor Call August 6, 2026 |
| 31 Jul 2026 |
8-K: Other Events
Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma |
| 30 Jul 2026 |
8-K: Regulation FD Disclosure
CC-1 Vusolimogene oderparepvec-wtpg (TUDRIQEV ) in Combination with Nivolumab for the Treatment of Adults with Unresectable Advanced Cutaneous Melanoma July 30, 2026 United States Food and Drug Administration Cellular, Tissue and Gene Th... |
| 29 Jun 2026 |
8-K: Results of Operations and Financial Condition
Woburn, MA, June 29, 2026 – Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal fourth quarter and y... |
| 26 Jun 2026 |
8-K: Regulation FD Disclosure
WOBURN, Mass., June 26, 2026 (GLOBE NEWSWIRE) - Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, announced today that the U.S. Food and Drug Admin... |
| 29 May 2026 |
8-K: Regulation FD Disclosure
WOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) - Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that following collaborative commu... |
| 13 Apr 2026 |
8-K: Regulation FD Disclosure; Other Events
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma |
| 03 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more
April 10, 2026 Target Action Date for RP1 in Advanced Melanoma |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure
© 2026 Replimune Group Inc. JPM 2026 Presentation Click to edit Master title style 1 Click to edit Master text styles Igniting a systemic immune response to cancer with oncolytic immunotherapy January 14, 2026 JPM Healthcare Conference |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
Woburn, MA, November 6, 2025 – Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal second quarter en... |
| 20 Oct 2025 |
8-K: Other Events
Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026 |
| 18 Sep 2025 |
8-K: Regulation FD Disclosure; Other Events
WOBURN, Mass., Sept 18, 2025 – Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the company completed a Type A meeting with t... |
| 04 Sep 2025 |
8-K: Submission of Matters to a Vote of Security Holders; Regulation FD Disclosure
Woburn, MA, Sept. 2, 2025 – Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that a Type A meeting with the U.S. Food and Drug Adm... |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
Woburn, MA, August 7, 2025 – Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal first quarter ended... |
| 22 Jul 2025 |
8-K: Regulation FD Disclosure; Other Events
Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma |
| 24 Jun 2025 |
8-K: Regulation FD Disclosure
As previously announced, Replimune Group, Inc. (the “Company”) hosted an Investor Day on Tuesday, June 24, 2025 at 10:00 a.m. ET. The audio webcast and accompanying updated investor event presentation deck is available under “Events and ... |
Loading...